Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Loading in …3
×
1 of 7

SWOT Analysis of Sanofi

7

Share

Download to read offline

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

SWOT Analysis of Sanofi

  1. 1. SANOFI BECAUSE HEALTH MATTERS By Lakshmi Ananth JobinThomas
  2. 2. HISTORY & LEGACY • Founded in 1956 4pas Hoechst Fedco Pharma pvt. Limited. • Merged with Roussel India Limited in 1997 to form Hoechst Marion Roussel Limited. • Globally acquired Aventis in 2001 and rebranded as Sanofi (in May 2011) Subsidiary Company Main Operation Sanofi Pasteur (from 1996) Vaccine division Shantha Biotechnics (from 1993) Biotech company for research in rare diseases Genzyme (from 2011) Recombinant health care products Chattem (from 2010) OTC products Zentiva Generic products Medley Contract Manufacturing Nichi-Iko & Merial Generic products
  3. 3. Major Therapeutic Areas • Cardiovascular Diseases • Thrombosis • Diabetes • Internal Medicine • Veterinary Medicines • Central Nervous System • Oncology • Arthritis and Osteoporosis • Consumer Health Care Due to world-class R&D pipeline, Sanofi India has leading positions in the following major therapeutic areas:
  4. 4. SWOT Analysis STRENGTHS • Fourth largest company by prescription sales • Market leadership in vaccines with Sanofi Pasteur • Oncology pipeline has more than 15 molecules. • Usage of renewable energy for manufacturing site • Very good in conducting Social Responsibilities like tuberculosis awareness programmes, diabetes awareness programmes etc., OPPURTUNITIES • Can capture entire African Market and expansion to new geographical areas. • Genzyme has given its considerable presence in uncommon diseases. • Population growth and increase of purchasing power of developing countries. • Marketing agreements with leading companies in developing and developed countries.
  5. 5. SWOT Analysis WEAKNESS • Employee generated lot of negative publicity for company. • Very small business units (Only 2 business units in Goa & Anklaleswar). • Patent expiry of most of blockbuster drugs (Plavix® and Lovenox®). • Low R&D productivity. THREATS • Global economic slowdown as major of company’s revenue is based on Exports. • Chance of losing market because of quality Issues (Combiflam® withdrawal in May 2016). • Stringent regulations in new drug development. • Increase in generic competition.
  6. 6. LITERATURE & RESOURCES • Sanofi India Official Website(http://www.sanofi.in/) • Statement on the recall of Combiflam® batches, May 23rd 2016. • Financial Results for the Q1, June 30, 2016. • Zentiva International Website(http://www.zentiva.com/) • Shantha Biotechnics Website (http://shanthabiotech.com/) • Sanofi Genzyme Website (https://www.sanofigenzyme.com/)
  7. 7. ThankYou.! BECAUSE HEALTH MATTERS SANOFI

×